A Quality by Design Approach in Pharmaceutical Development of Non-Viral Vectors with a Focus on miRNA
Cancer is the leading cause of death worldwide. Tumors consist of heterogeneous cell populations that have different biological properties. While conventional cancer therapy such as chemotherapy, radiotherapy, and surgery does not target cancer cells specifically, gene therapy is attracting increasi...
Main Authors: | Ioana Toma, Alina Silvia Porfire, Lucia Ruxandra Tefas, Ioana Berindan-Neagoe, Ioan Tomuță |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/7/1482 |
Similar Items
-
Recent Advances in miRNA Delivery Systems
by: Ishani Dasgupta, et al.
Published: (2021-01-01) -
Clinical Advances in Viral-Vectored Influenza Vaccines
by: Sarah Sebastian, et al.
Published: (2018-05-01) -
Developments in Viral Vector-Based Vaccines
by: Takehiro Ura, et al.
Published: (2014-07-01) -
miRNA Delivery by Nanosystems: State of the Art and Perspectives
by: Fernanda C. Moraes, et al.
Published: (2021-11-01) -
Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya
by: Christiane Gerke, et al.
Published: (2019-04-01)